CN102048761A - 一种水蛭为原料的肠溶片的制备方法 - Google Patents
一种水蛭为原料的肠溶片的制备方法 Download PDFInfo
- Publication number
- CN102048761A CN102048761A CN2010105956070A CN201010595607A CN102048761A CN 102048761 A CN102048761 A CN 102048761A CN 2010105956070 A CN2010105956070 A CN 2010105956070A CN 201010595607 A CN201010595607 A CN 201010595607A CN 102048761 A CN102048761 A CN 102048761A
- Authority
- CN
- China
- Prior art keywords
- hirudo
- freezing
- raw material
- preparation
- coatel tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000002994 raw material Substances 0.000 title claims abstract description 15
- 241000545744 Hirudinea Species 0.000 title abstract description 5
- 239000002662 enteric coated tablet Substances 0.000 title abstract 3
- 238000007710 freezing Methods 0.000 claims abstract description 56
- 230000008014 freezing Effects 0.000 claims abstract description 56
- 238000005360 mashing Methods 0.000 claims abstract description 24
- 230000001954 sterilising effect Effects 0.000 claims abstract description 23
- 241000237903 Hirudo Species 0.000 claims description 105
- 239000000203 mixture Substances 0.000 claims description 21
- 238000004659 sterilization and disinfection Methods 0.000 claims description 21
- 238000001291 vacuum drying Methods 0.000 claims description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 17
- 229920002472 Starch Polymers 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000000314 lubricant Substances 0.000 claims description 15
- 239000008107 starch Substances 0.000 claims description 15
- 235000019698 starch Nutrition 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000000945 filler Substances 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- 239000008101 lactose Substances 0.000 claims description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- 229950005770 hyprolose Drugs 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 235000019890 Amylum Nutrition 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 39
- 238000000034 method Methods 0.000 abstract description 35
- 230000008569 process Effects 0.000 abstract description 24
- 239000004019 antithrombin Substances 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 9
- 238000001035 drying Methods 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 43
- 210000001519 tissue Anatomy 0.000 description 24
- 239000007788 liquid Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000002002 slurry Substances 0.000 description 10
- 102000007625 Hirudins Human genes 0.000 description 6
- 108010007267 Hirudins Proteins 0.000 description 6
- 229940006607 hirudin Drugs 0.000 description 6
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105956070A CN102048761B (zh) | 2010-12-20 | 2010-12-20 | 一种水蛭为原料的肠溶片的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105956070A CN102048761B (zh) | 2010-12-20 | 2010-12-20 | 一种水蛭为原料的肠溶片的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102048761A true CN102048761A (zh) | 2011-05-11 |
CN102048761B CN102048761B (zh) | 2012-02-15 |
Family
ID=43953778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105956070A Active CN102048761B (zh) | 2010-12-20 | 2010-12-20 | 一种水蛭为原料的肠溶片的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102048761B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727118A (zh) * | 2016-12-16 | 2017-05-31 | 华南协同创新研究院 | 一种燕麦生物碱的提取方法及应用 |
CN107397731A (zh) * | 2017-07-25 | 2017-11-28 | 重庆多普泰制药股份有限公司 | 一种脉血康素片、肠溶片剂及其制备方法 |
CN107412269A (zh) * | 2017-08-03 | 2017-12-01 | 重庆多普泰制药股份有限公司 | 一种以水蛭为原料的肠溶片剂及其制备方法 |
CN107595891A (zh) * | 2017-09-11 | 2018-01-19 | 重庆多普泰制药股份有限公司 | 一种水蛭加工工艺 |
CN107823156A (zh) * | 2017-11-22 | 2018-03-23 | 广西远程水蛭养殖有限公司 | 水蛭含片制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1156034A (zh) * | 1996-02-14 | 1997-08-06 | 湖北省中医药研究院 | 脉血康肠溶制剂的制备方法 |
CN1857321A (zh) * | 2006-03-21 | 2006-11-08 | 陈志成 | 一种疏血通注射剂的制备方法 |
CN101579360A (zh) * | 2008-12-24 | 2009-11-18 | 贵州信邦制药股份有限公司 | 高活性蛭类动物提取物在制备药物中的应用及其制法 |
CN102028712A (zh) * | 2010-12-20 | 2011-04-27 | 重庆时珍阁普生药业有限公司 | 一种水蛭为原料的肠溶胶囊的制备方法 |
-
2010
- 2010-12-20 CN CN2010105956070A patent/CN102048761B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1156034A (zh) * | 1996-02-14 | 1997-08-06 | 湖北省中医药研究院 | 脉血康肠溶制剂的制备方法 |
CN1857321A (zh) * | 2006-03-21 | 2006-11-08 | 陈志成 | 一种疏血通注射剂的制备方法 |
CN101579360A (zh) * | 2008-12-24 | 2009-11-18 | 贵州信邦制药股份有限公司 | 高活性蛭类动物提取物在制备药物中的应用及其制法 |
CN102028712A (zh) * | 2010-12-20 | 2011-04-27 | 重庆时珍阁普生药业有限公司 | 一种水蛭为原料的肠溶胶囊的制备方法 |
Non-Patent Citations (4)
Title |
---|
《中国医疗前沿》 20070630 王春涛等 水蛭注射液的制备及鉴别 , 第12期 2 * |
《中药材》 20070331 王厚伟 低温炮制工艺对水蛭水溶性蛋白组成及纤溶活性的影响 , 第03期 2 * |
《安徽农业科学》 20081130 韩志等 水蛭冷冻干燥过程优化及最佳工艺条件的确立 , 第31期 2 * |
《沈阳药科大学学报》 20051130 王征等 重组水蛭素肠溶包衣微丸的制备及体外释放行为考察 , 第06期 2 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727118A (zh) * | 2016-12-16 | 2017-05-31 | 华南协同创新研究院 | 一种燕麦生物碱的提取方法及应用 |
CN106727118B (zh) * | 2016-12-16 | 2019-12-03 | 华南协同创新研究院 | 一种燕麦生物碱的提取方法及应用 |
CN107397731A (zh) * | 2017-07-25 | 2017-11-28 | 重庆多普泰制药股份有限公司 | 一种脉血康素片、肠溶片剂及其制备方法 |
CN107412269A (zh) * | 2017-08-03 | 2017-12-01 | 重庆多普泰制药股份有限公司 | 一种以水蛭为原料的肠溶片剂及其制备方法 |
CN107595891A (zh) * | 2017-09-11 | 2018-01-19 | 重庆多普泰制药股份有限公司 | 一种水蛭加工工艺 |
CN107823156A (zh) * | 2017-11-22 | 2018-03-23 | 广西远程水蛭养殖有限公司 | 水蛭含片制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102048761B (zh) | 2012-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048761B (zh) | 一种水蛭为原料的肠溶片的制备方法 | |
CN102631377B (zh) | 冬虫夏草冻干纳米粉片及其制备方法 | |
CN102793733A (zh) | 人参蜂王浆咀嚼片及其制备方法 | |
CN104288227A (zh) | 一种中药鲜药材的新型干燥方法及其应用 | |
CN102028712B (zh) | 一种水蛭为原料的肠溶胶囊的制备方法 | |
CN103393821B (zh) | 一种治疗慢性盆腔炎的中药组合物及其制备方法 | |
CN105853484A (zh) | 三七原粉片的制备方法 | |
US20210007966A1 (en) | Skincare composition containing plant extracts and preparation method thereof | |
WO2015010498A1 (zh) | 快速清理身体代谢毒素的天然草本组合物 | |
CN102743503B (zh) | 一种治疗奶牛子宫内膜炎的中药复方泡腾片制备方法 | |
CN101380294B (zh) | 一种治疗出血病的固体分散药物制备方法 | |
Nawrin et al. | Antipyretic, antidiabetic, thrombolytic and CNS depressant potential of ethanol extract of Crotalaria verrucosa L. leaves | |
CN103211880B (zh) | 一种余甘子复方胶囊及其制备方法 | |
CN102370901A (zh) | 一种治疗肾病的药物组合物及其制备方法 | |
CN105267264A (zh) | 一种全当归胶囊制备工艺及全当归胶囊 | |
CN101732662B (zh) | 一种治疗盆腔炎的中药组合物及其制备方法 | |
CN103520182A (zh) | 一种治疗肝纤维药物组合物及其制备方法 | |
KR101023487B1 (ko) | 오미자, 황금 및 해동피의 혼합 생약재 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
CN101417004A (zh) | 一种具有解热抗炎、保肝利胆功能的兽用药的制备方法 | |
CN107496295A (zh) | 祛痘酵素面膜粉及其制备方法 | |
CN102727804B (zh) | 一种治疗脓疮、疖子的中药组合物及其制备方法 | |
CN110897982A (zh) | 一种蚓激酶冻干粉及其在护肤品中的应用 | |
KR102114978B1 (ko) | 황련 추출물을 포함하는 갑상선 질환 예방 및 치료용 조성물 | |
CN113967229B (zh) | 一种治疗静脉炎的中药组合物及其制备方法和应用 | |
CN107737191A (zh) | 一种补肾强身的肉苁蓉组合物及制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant before: CHONGQING SHIZHENGE PUSHENG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHONGQING SHIZHEN'GE PUSHENG PHARMACEUTICAL CO., LTD. TO: CHONGQING DUOPUTAI PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Cao Jia Dian 400800 Chongqing city Wansheng District East Qingxi Bridge Patentee after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Patentee before: Chongqing Duoputai Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240122 Address after: No. 303-7, Qingxi Bridge, Donglin Street, Wansheng Economic Development Zone, Qijiang District, Chongqing, 400800 Patentee after: Chongqing Duoputai Pharmaceutical Technology Co.,Ltd. Address before: 400800 Donglin Qingxi bridge in Wansheng District, Chongqing Patentee before: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |